Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in Portopulmonary Hypertension
NCT00145938Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Sep 2003
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sildenafil in portopulmonary hypertension (POPH), sponsored by University of Chicago. Primary endpoint: Mean Pulmonary Artery Pressure at 12 weeks. Started Sep 2003; status: terminated.
02
Drugs
sildenafil
03
Conditions
portopulmonary hypertension (POPH)
Beyond the preview
Go deeper on NCT00145938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00145938.